Deals this week: Elekta AB, Pulse Biosciences, Caresyntax

28 September 2017 (Last Updated September 28th, 2017 18:30)

Elekta AB has signed a memorandum of understanding (MOU) with Belgian company Ion Beam Applications SA (IBA) to collaborate on the development of software and market their products.

Elekta AB has signed a memorandum of understanding (MOU) with Belgian company Ion Beam Applications SA (IBA) to collaborate on the development of software and market their products.

The agreement will enable the companies to advance the development of proton therapy treatments.

Based in Sweden, Elekta provides clinical solutions for the treatment of cancer and brain disorders.

US-based company Pulse Biosciences Inc plans to raise $30.04m through the private placement of two million shares of its common stock priced at $15.02 each.

The company plans to use the funds towards working capital and general corporate purposes.

"The agreement will enable the companies to advance the development of proton therapy treatments."

Caresyntax Inc has secured $11.9m in a venture financing round led by Norgine Ventures Management Limited.

The US-based surgical analytics and integration services company plans to use the funds towards product development and to open a new headquarters in Boston.

Chinese medical devices developer Lepu Medical Technology (Beijing) Co Ltd plans to raise CNY3bn ($454.68m) by issuing exchangeable bonds in a private placement.

Discgenics Inc has secured $14m in a series B financing round led by existing investors and Mitsubishi UFJ Capital Co Ltd.

The US-based regenerative medicine company plans to use the funds for the development of its Injectable Discosphere Cell Therapy (IDCT) product in the US and Japan.